Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
A Hochhaus, P La Rosée - Leukemia, 2004 - nature.com
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
HM Kantarjian, M Talpaz, F Giles, S O'Brien… - Annals of internal …, 2006 - acpjournals.org
Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a
single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein …
single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein …
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
D Marin, A Bazeos, FX Mahon, L Eliasson… - Journal of clinical …, 2010 - ascopubs.org
Purpose There is a considerable variability in the level of molecular responses achieved
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B Hanfstein, MC Müller, R Hehlmann, P Erben… - Leukemia, 2012 - nature.com
In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …
Dynamics of chronic myeloid leukaemia
The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid
leukaemia (CML) serves as a model for molecularly targeted therapy of cancer,,,, but at least …
leukaemia (CML) serves as a model for molecularly targeted therapy of cancer,,,, but at least …
Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts
A Arocho, B Chen, M Ladanyi… - Diagnostic Molecular …, 2006 - journals.lww.com
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is
characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 …
characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 …
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
AR Ibrahim, L Eliasson, JF Apperley… - Blood, The Journal …, 2011 - ashpublications.org
We studied the relation between adherence to imatinib measured with microelectronic
monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) …
monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) …
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
M Koptyra, R Falinski, MO Nowicki, T Stoklosa… - Blood, 2006 - ashpublications.org
Mutations in the BCR/ABL kinase domain play a major role in resistance to imatinib
mesylate (IM). We report here that BCR/ABL kinase stimulates reactive oxygen species …
mesylate (IM). We report here that BCR/ABL kinase stimulates reactive oxygen species …